Nurix Therapeutics, Inc. - 8-K Filing Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2021 Annual Meeting of Stockholders held virtually on May 6, 2021. The registrant, Nurix Therapeutics, Inc., is an emerging growth company incorporated in Delaware with its principal executive offices in San Francisco, California.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting. A total of 34,460,833 shares were present, representing approximately 77.76% of the voting power, constituting a quorum.
- Proposal 1: Election of Directors
- David Lacey, M.D.: Elected with 30,425,290 votes for, 1,965,511 votes withheld, and 2,070,032 broker non-votes.
- Julia P. Gregory: Elected with 26,971,638 votes for, 5,419,163 votes withheld, and 2,070,032 broker non-votes.
- Both directors were elected to serve three-year terms expiring at the 2024 annual meeting.
- Proposal 2: Ratification of Independent Auditor
- Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending November 30, 2021.
- Votes For: 34,381,976; Votes Against: 77,979; Abstentions: 878.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation that David Lacey, M.D., and Julia P. Gregory have officially assumed their roles as Class I directors.
- Verification of PricewaterhouseCoopers LLP's engagement for the fiscal year ending November 30, 2021.
- Review of the definitive proxy statement filed on March 25, 2021, for detailed background on the nominees and proposals.